Immunity during thymostimulin therapy in advanced neuroblastoma

C. Rosanda, G. Pastore, E. Lanino, A. Garaventa, B. De Bernardi

Research output: Contribution to journalArticlepeer-review


Eighty children with non-localized neuroblastoma were treated in a randomized clinical trial, either with chemotherapy alone (cyclophosphamide and doxorubicin in monthly sequential cycles), or with the same chemotherapy associated with the thymic extract TP-1 (Serono) given in the intervals between chemotherapy cycles. TP-1 administration did not influence immune status, as assessed by total white blood cell count, total lymphocyte count and T and B cell count, levels of serum immunoglobulins (IgG, IgA, IgM), and of complement fractions C3-C4. Percentages of patients achieving either complete or partial remission, or percentages of survivors, were not significantly affected; however, patients receiving TP-1 developed significantly less infectious episodes than the control group.

Original languageEnglish
Pages (from-to)173-181
Number of pages9
JournalPediatric Hematology and Oncology
Issue number1
Publication statusPublished - 1985


  • Immunotherapy
  • Neuroblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology


Dive into the research topics of 'Immunity during thymostimulin therapy in advanced neuroblastoma'. Together they form a unique fingerprint.

Cite this